Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Clinical phase II trial data has shown a combination of Genentech/Roche's Avastin and Pfizer's Camptosar to confer antitumor activity in the treatment of glioma. Although Avastin has already reached blockbuster status in other indications, the severe unmet needs and lack of alternative treatment options in this patient population mean that, if approved, eventual uptake is likely to be promising.
Published By Datamonitor
|
19 Feb 2007 |
|
CommentWire
|
Positive trial data for Avastin drove Genentech's [DNA] share price up by almost 25% and parent company Roche's [ROCZ.S] share price by over 5%. Roche and Genentech have partnered to form the largest global player for cancer drugs, and Avastin looks set to provide them with another superstar product. Genentech's future as a major biotech player in the cancer market thus seems assured.
Published By Datamonitor
|
16 Mar 2005 |
|
CommentWire
|
Genentech looks set to add Avastin to its growing number of successfully marketed innovative products, judging by the announcement of positive phase III clinical trial results in colorectal cancer patients. The results pave the way for Avastin to be launched in late 2004, making it the first angiogenesis inhibitor available for the treatment of colorectal cancer.
Published By Datamonitor
|
20 May 2003 |
|
CommentWire
|
Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.
Published By Datamonitor
|
14 Aug 2008 |
|
CommentWire
|
A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />
Published By Datamonitor
|
13 Dec 2002 |
|
CommentWire
|
The Swiss agency for therapeutic products has approved Erbitux for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. This is likely to be followed by approval across Europe, where it should provide Merck KGaA [MRK.F] with annual sales of more than $260 million by 2008.
Published By Datamonitor
|
04 Dec 2003 |
|
Expert View
|
Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />
Published By Datamonitor
|
08 Aug 2002 |
|
CommentWire
|
Swiss regulators have recommended the approval of Merck KGaA's [MRK.F] Erbitux as a second-line therapy for colorectal cancer. The drug is set to be approved within 30 days and Switzerland will be the first market to approve the drug. Given Erbitux's past difficulties, it is welcome news, not only for Merck, but also for ImClone [IMCL] and BMS [BMY].
Published By Datamonitor
|
17 Nov 2003 |
|
Expert View
|
Novartis has agreed to acquire a controlling stake in ophthalmology specialist Alcon for around $39 billion, revealing a clear intention to drive diversification from its core prescription pharmaceutical business. Although Alcon will not come cheap, the acquisition represents a positive, long-term strategy by Novartis which faces intensifying generic competition over the next five years.
Published By Datamonitor
|
08 Apr 2008 |
|
Expert View
|
Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).
Published By Datamonitor
|
09 Jun 2005 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.